{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:12:28Z","timestamp":1768525948232,"version":"3.49.0"},"posted":{"date-parts":[[2025,10,17]]},"group-title":"Microbiology","reference-count":59,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Mouse models have been key to studies of tuberculosis pathogenesis and drug efficacy, but many, such as those employing BALB\/c mice, fail to reproduce the full range of heterogenous microniches observed in well-structured human lesions, which feature hypoxic caseous cores of necrotic debris surrounded by infected foamy macrophages. The granuloma presents a variety of environments differing in levels of oxygen, ions, nutrients, and intra versus extracellular residence, which determine the physiological state of the infecting bacillus and its susceptibility to immune or drug control. Recently, alternative mouse strains such as C3HeB\/FeJ have allowed the study of infection and treatment in the context of these varied environments but exhibit substantial inconsistency in development of human-like lesions, both within and between individual mice. Building on the observation that inducible nitric oxide synthase (\n                  <jats:italic>Nos2<\/jats:italic>\n                  )-deficient mice consistently develop hypoxic necrotic lesions, we have established two simplified models with infection by the aerosol route. The first uses the slightly attenuated\n                  <jats:italic>M. tuberculosis<\/jats:italic>\n                  R1Rv strain, which produces a progressive infection that is contained at a high stable burden by an adaptive immune response. In the second model, vaccination with the attenuated \u0394\n                  <jats:italic>RD1<\/jats:italic>\n                  , pantothenate auxotroph mc\n                  <jats:sup>2<\/jats:sup>\n                  6230 protects from an otherwise lethal infection with virulent\n                  <jats:italic>M. tuberculosis<\/jats:italic>\n                  Erdman. This model reflects most contemporary tuberculosis infections, which take place in the context of a pre-existing immune response from vaccination. Both variations uniformly develop well-structured hypoxic necrotic lesions harboring drug tolerant bacteria. These refined models will be useful in studies of\n                  <jats:italic>M. tuberculosis<\/jats:italic>\n                  infection and treatment.\n                <\/jats:p>","DOI":"10.1101\/2025.10.17.683099","type":"posted-content","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:14Z","timestamp":1760733614000},"source":"Crossref","is-referenced-by-count":0,"title":["Mouse Models Uniformly Featuring Human-like Lesions Harboring Drug-tolerant\n                  <i>Mycobacterium tuberculosis<\/i>"],"prefix":"10.64898","author":[{"given":"Ga\u00eblle Guiewi","family":"Makafe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Low-Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Travis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Bernacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Duso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Kummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tricia","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Roemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Reiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Tighe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0880-4487","authenticated-orcid":false,"given":"Brian","family":"Weinrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"6","key":"2025102109100587000_2025.10.17.683099v1.1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tube.2012.07.003","article-title":"Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis","volume":"92","year":"2012","journal-title":"Tuberculosis (Edinb"},{"key":"2025102109100587000_2025.10.17.683099v1.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200407-885OC"},{"key":"2025102109100587000_2025.10.17.683099v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407426"},{"key":"2025102109100587000_2025.10.17.683099v1.4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir786"},{"key":"2025102109100587000_2025.10.17.683099v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/nri3211"},{"issue":"3","key":"2025102109100587000_2025.10.17.683099v1.6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tube.2009.02.002","article-title":"Man and mouse TB: contradictions and solutions","volume":"89","year":"2009","journal-title":"Tuberculosis (Edinb)"},{"key":"2025102109100587000_2025.10.17.683099v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2005.01.005"},{"key":"2025102109100587000_2025.10.17.683099v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"key":"2025102109100587000_2025.10.17.683099v1.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00217-12"},{"key":"2025102109100587000_2025.10.17.683099v1.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-15"},{"key":"2025102109100587000_2025.10.17.683099v1.11","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.019570"},{"issue":"4","key":"2025102109100587000_2025.10.17.683099v1.12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB\/FeJ Mice","volume":"2","year":"2016","journal-title":"ACS Infect Dis"},{"key":"2025102109100587000_2025.10.17.683099v1.13","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.019513"},{"key":"2025102109100587000_2025.10.17.683099v1.14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI42796"},{"key":"2025102109100587000_2025.10.17.683099v1.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09177-2"},{"key":"2025102109100587000_2025.10.17.683099v1.16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021186"},{"issue":"5","key":"2025102109100587000_2025.10.17.683099v1.17","first-page":"577","article-title":"The history of the R1 strain of tubercle bacillus","volume":"25","year":"1932","journal-title":"American Review of Tuberculosis"},{"key":"2025102109100587000_2025.10.17.683099v1.18","first-page":"51","article-title":"R1 strain of tubercle bacillus; its dissociation and virulence of variants in normal and silicotic guinea pigs","volume":"54","year":"1946","journal-title":"Am Rev Tuberc"},{"key":"2025102109100587000_2025.10.17.683099v1.19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021186"},{"key":"2025102109100587000_2025.10.17.683099v1.20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202101-0032OC"},{"key":"2025102109100587000_2025.10.17.683099v1.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.10.5243"},{"key":"2025102109100587000_2025.10.17.683099v1.22","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.68.12.6879-6882.2000"},{"key":"2025102109100587000_2025.10.17.683099v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.097"},{"key":"2025102109100587000_2025.10.17.683099v1.24","doi-asserted-by":"crossref","unstructured":"Jain, P. , et al., Dual-Reporter Mycobacteriophages (Phi2DRMs) Reveal Preexisting Mycobacterium tuberculosis Persistent Cells in Human Sputum. MBio, 2016. 7(5).","DOI":"10.1128\/mBio.01023-16"},{"key":"2025102109100587000_2025.10.17.683099v1.25","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01515-07"},{"key":"2025102109100587000_2025.10.17.683099v1.26","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir786"},{"key":"2025102109100587000_2025.10.17.683099v1.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00217-12"},{"key":"2025102109100587000_2025.10.17.683099v1.28","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1038\/s41598-017-09177-2","article-title":"NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans","volume":"7","year":"2017","journal-title":"Scientific Reports"},{"key":"2025102109100587000_2025.10.17.683099v1.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202722"},{"key":"2025102109100587000_2025.10.17.683099v1.30","doi-asserted-by":"publisher","DOI":"10.1002\/path.4399"},{"key":"2025102109100587000_2025.10.17.683099v1.31","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.2.127"},{"key":"2025102109100587000_2025.10.17.683099v1.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.6.2294-2301.2005"},{"key":"2025102109100587000_2025.10.17.683099v1.33","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-1043-7"},{"issue":"9940","key":"2025102109100587000_2025.10.17.683099v1.34","first-page":"1705","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"384","year":"2014","journal-title":"The Lancet"},{"key":"2025102109100587000_2025.10.17.683099v1.35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06125-11"},{"key":"2025102109100587000_2025.10.17.683099v1.36","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/IDR.S499816","article-title":"Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity Study","volume":"18","year":"2025","journal-title":"Infect Drug Resist"},{"issue":"2","key":"2025102109100587000_2025.10.17.683099v1.37","first-page":"155","article-title":"Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis","volume":"86","year":"1996","journal-title":"S Afr Med J"},{"key":"2025102109100587000_2025.10.17.683099v1.38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02637-15"},{"issue":"8","key":"2025102109100587000_2025.10.17.683099v1.39","first-page":"4476","article-title":"Moxifloxacin kills persistent Mycobacterium tuberculosis with high efficiency","volume":"56","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"2025102109100587000_2025.10.17.683099v1.40","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200310-1380OC"},{"key":"2025102109100587000_2025.10.17.683099v1.41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"2025102109100587000_2025.10.17.683099v1.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05293-11"},{"issue":"9","key":"2025102109100587000_2025.10.17.683099v1.43","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","year":"2000","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"key":"2025102109100587000_2025.10.17.683099v1.44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00074-08"},{"issue":"2","key":"2025102109100587000_2025.10.17.683099v1.45","first-page":"367","article-title":"The antituberculous activity of pyrazinamide in vitro and in the guinea pig","volume":"70","year":"1954","journal-title":"Am Rev Tuberc"},{"issue":"3","key":"2025102109100587000_2025.10.17.683099v1.46","first-page":"782","article-title":"Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice","volume":"49","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"7","key":"2025102109100587000_2025.10.17.683099v1.47","first-page":"1620","article-title":"Effects of chemotherapy on the emergence of isoniazid-resistant mutants of Mycobacterium tuberculosis in the murine model","volume":"40","year":"1996","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"2025102109100587000_2025.10.17.683099v1.48","first-page":"e00250","article-title":"Clade-specific virulence patterns of Mycobacterium tuberculosis complex strains in human primary macrophages and correlation with epidemiological data","volume":"4","year":"2013","journal-title":"mBio"},{"key":"2025102109100587000_2025.10.17.683099v1.49","doi-asserted-by":"crossref","first-page":"17072","DOI":"10.1038\/nmicrobiol.2017.72","article-title":"Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis","volume":"2","year":"2017","journal-title":"Nat Microbiol"},{"key":"2025102109100587000_2025.10.17.683099v1.50","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2015.1084502"},{"key":"2025102109100587000_2025.10.17.683099v1.51","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12252"},{"key":"2025102109100587000_2025.10.17.683099v1.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901814"},{"key":"2025102109100587000_2025.10.17.683099v1.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313865"},{"issue":"1","key":"2025102109100587000_2025.10.17.683099v1.54","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","year":"2003","journal-title":"International Journal of Tuberculosis and Lung Disease"},{"key":"2025102109100587000_2025.10.17.683099v1.55","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01370-15"},{"issue":"12","key":"2025102109100587000_2025.10.17.683099v1.56","first-page":"1465","article-title":"Short-course regimens for multidrug-resistant tuberculosis in China: A systematic review and meta-analysis","volume":"16","year":"2012","journal-title":"The International Journal of Tuberculosis and Lung Disease"},{"issue":"4","key":"2025102109100587000_2025.10.17.683099v1.57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-3083.1990.tb02790.x","article-title":"Secretory component-binding properties of normal serum IgM","volume":"31","year":"1990","journal-title":"Scand J Immunol"},{"key":"2025102109100587000_2025.10.17.683099v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3200"},{"key":"2025102109100587000_2025.10.17.683099v1.59","unstructured":"Orme, I.M. and A.D. Roberts , Animal models of mycobacteria infection. Curr Protoc Immunol, 2001. Chapter 19: p. Unit 19 5."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.17.683099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:50:11Z","timestamp":1768470611000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.10.17.683099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1101\/2025.10.17.683099","relation":{},"subject":[],"published":{"date-parts":[[2025,10,17]]},"subtype":"preprint"}}